Federal Register / Vol. 80, No. 52 / Wednesday, March 18, 2015 / Notices 14141 

information collection. This is a onetime data collection effort. 

CDC will use the information to 

examine health systems and 

dissemination of health systems 

technology. Primary care practices will 

use the results to inform their systems 

for managing patients with chronic 

conditions and to improve the quality of 

care delivered. NCHS and CDC will also 

use the results to improve technical 

assistance to public health partners. 

OMB approval is requested for two 

years. Participation in the survey is 

voluntary and all responses CDC will 

de-identify all responses. There are no 

costs to respondents other than their 

time. The total estimated annualized 

burden hours are 429. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Physician ......................................................... Cognitive Testing Screener ............................ 25 1 5/60 

Physician ......................................................... Cognitive Testing Protocol ............................. 15 1 1.25 

Medical Secretary ........................................... NSPCP Screener ........................................... 1,500 1 10/60 

Physician ......................................................... NSPCP ........................................................... 473 1 20/60 

Leroy A. Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2015–06159 Filed 3–17–15; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the Board 

of Scientific Counselors, NIAMS. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, 

including consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, NIAMS. 

Date: April 15–16, 2015. 

Time: 6:00 p.m. to 3:45 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, 

Building 31, Room 4C32, 31 Center Drive, 

Bethesda, MD 20892. 

Contact Person: John J. O’Shea, MD, Ph.D., 

Scientific Director, National Institute of 

Arthritis & Musculoskeletal and Skin 

Diseases, Building 10, Room 9N228, MSC 

1820, Bethesda, MD 20892, (301) 496–2612, 

osheaj@arb.niams.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS). 

Dated: March 12, 2015. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–06122 Filed 3–17–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 209 and 37 CFR part 404 to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

U.S. patent applications listed below 

may be obtained by writing to the 

indicated licensing contact at the Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

GTF2I Mutations as Genetic Marker for 

Prognosis of Thymic Malignancies 

Description of Technology: The 

present invention describes the 

presence of a mutation in the general 

transcription factor IIi (GTF2I) gene in 

indolent thymic tumors that is rarely 

found in more aggressive thymic 

tumors. 

The invention provides a method of 

determining the prognosis of thymic 

cancer in a patient by assaying (for 

example using PCR based methods) the 

genetic material obtained from the 

patient tissue to detect a mutation in at 

least one copy of GTF2I genetic 

sequence; and correlating the presence 

of a GTF2I mutation with the prognosis 

of a thymic cancer patient, the presence 

of the mutation indicating that the 

thymic cancer is indolent. 

A genetic test will complement the 

diagnostic assessment, facilitate 

development of a molecular 

classification and assessment for the 

clinical management of thymic cancers. 

Potential Commercial Applications: 

• A diagnostic test kit for the 

prognosis and clinical management of 

thymic cancer. 

• Clinical decision whether treatment 

is needed (for example, additional 

treatment after surgery). 

• Therapeutic decision making, 

between an aggressive course of 

mstockstill on DSK4VPTVN1PROD with NOTICES